<p>根据最近向证券交易委员会提交的 13F 文件，沃州银行在 2023 年第四季度将其在阿尼拉姆制药公司（NASDAQ:ALNY - 免费报告）股票中的持股比例提高了 127.1%。该公司在此期间额外购买了 6,177 股后，持有 11,037 股生物制药公司的股票。根据其最近的 SEC 文件，沃州银行在阿尼拉姆制药的持股价值为 4,390,000 美元。</p>
<ul>
<li>阿尼拉姆股票飙升 65%：了解背后的原因</li>
</ul>
<p>其他一些机构投资者最近也调整了他们在 ALNY 的持股。Root Financial Partners LLC 在第三季度收购了价值 25,000 美元的阿尼拉姆制药新股份。凯通国际资产管理有限公司在第三季度收购了价值 29,000 美元的阿尼拉姆制药新股份。Ameriflex Group Inc.在第三季度收购了价值 32,000 美元的阿尼拉姆制药新股份。Aster Capital Management DIFC Ltd 在第三季度收购了价值 36,000 美元的阿尼拉姆制药新股份。最后，Newbridge Financial Services Group Inc.在第三季度收购了价值 39,000 美元的阿尼拉姆制药新股份。机构投资者和对冲基金持有该公司 92.97% 的股票。</p>
<h2>内部活动</h2>
<p>在其他新闻中，内部人士梅丽莎·麦克劳林于 4 月 6 日星期一出售了 2,286 股公司的股票。该股票以平均价格 330.42 美元出售，总交易额为 755,340.12 美元。交易完成后，内部人士直接持有公司 9,443 股，价值 3,120,156.06 美元。此次交易使其持股减少了 19.49%。该销售在向证券交易委员会的文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此次出售是为了覆盖与股权奖励归属相关的税收扣缴义务。此外，执行副总裁凯文·约瑟夫·菲茨杰拉德于 3 月 3 日星期二出售了 1,652 股公司的股票。该股票以平均价格 319.73 美元出售，总价值为 528,193.96 美元。交易完成后，执行副总裁持有公司 21,860 股，价值约 6,989,297.80 美元。此次交易使其持股减少了 7.03%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了价值 6,930,337 美元的 21,255 股公司股票。内部人士持有公司 0.86% 的股票。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
<p>几位股票研究分析师最近对 ALNY 股票发布了报告。Canaccord Genuity Group 将阿尼拉姆制药的目标价从 415.00 美元上调至 429.00 美元，并在 2 月 17 日的报告中给予该公司 “买入” 评级。美国银行在 2 月 12 日的报告中重申了对阿尼拉姆制药股票的 “买入” 评级。杰富瑞金融集团在 3 月 16 日的研究报告中重申了 “持有” 评级，并将阿尼拉姆制药的目标价设定为 330.00 美元（低于 522.00 美元）。Weiss Ratings 在 5 月 4 日的研究报告中将阿尼拉姆制药的评级从 “卖出（d+）” 上调至 “持有（c-）”。最后，Freedom Capital 在 2 月 17 日的研究报告中将阿尼拉姆制药的评级从 “持有” 上调至 “强烈买入”。两位研究分析师给予该股票 “强烈买入” 评级，十八位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat.com 的数据，阿尼拉姆制药目前的平均评级为 “适度买入”，共识目标价为 463.13 美元。</p>
<p><strong>查看我们对阿尼拉姆制药的最新分析</strong></p>
<h2>阿尼拉姆制药股票上涨 1.4%</h2>
<ul>
<li>阿根克斯 28% 的激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>阿尼拉姆制药的股票在周四以 298.48 美元开盘。该股票的市值为 398.5 亿美元，市盈率为 81.55，贝塔系数为 0.31。该公司的速动比率为 3.06，流动比率为 3.13，债务与股本比率为 0.94。该股票的 50 日移动平均价格为 312.06 美元，200 日移动平均价格为 361.02 美元。阿尼拉姆制药公司 12 个月低点为 284.19 美元，12 个月高点为 495.55 美元。</p>
<p>阿尼拉姆制药（NASDAQ:ALNY - 获取免费报告）最近于 4 月 30 日发布了其财报。这家生物制药公司报告了每股收益 1.99 美元，超出分析师一致预期的 0.87 美元，超出幅度为 1.12 美元。该公司在本季度的收入为 11.7 亿美元，而分析师预期为 11.2 亿美元。阿尼拉姆制药的净利润率为 11.72%，股本回报率为 85.76%。该公司的收入同比增长 96.4%。在去年同期，该公司每股收益为（0.44）美元。股票分析师预计阿尼拉姆制药将在当前年度发布每股收益 7.36 美元。</p>
<h2>关于阿尼拉姆制药</h2>
<p>（免费报告）</p>
<p>阿尼拉姆制药公司（NASDAQ: ALNY）是一家生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。公司成立的目的是将 RNAi 的科学发现转化为新药，阿尼拉姆利用小干扰 RNA（siRNA）技术来沉默致病基因。该公司开发的疗法旨在通过针对一系列罕见和更常见疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
<p>阿里拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc-结合化学以实现针对肝脏的靶向递送，并通过皮下给药。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比阿里拉姆制药更好的股票</li>
<li>从 Zepbound 到 Foundayo：礼来最新业绩支持口服 GLP-1 前景</li>
<li>人工智能整合开始：黑石与谷歌打造人工智能帝国</li>
<li>美国稀土公司在 2026 年第一季度发布强劲业绩，巨额 Serra Vera 交易即将到来</li>
<li>三只在 SpaceX IPO 前获得动力的太空基础设施股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在阿里拉姆制药吗？</h2>
<p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿里拉姆制药并不在名单上。</p>
<p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿里拉姆制药

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

<p>瑞士沃州银行在第四季度将其在阿里拉姆制药的股份增加了 127.1%，目前持有 11,037 股，价值 439 万美元。其他机构投资者也增持了该公司的股份。内部交易活动包括高管出售股票以支付税务义务。分析师设定了新的价格目标，普遍评级为 “适度买入”，平均目标价格为 463.13 美元</p>

<p>Banque Cantonale Vaudoise raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 127.1% in the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 11,037 shares of the biopharmaceutical company's stock after buying an additional 6,177 shares during the period. Banque Cantonale Vaudoise's holdings in Alnylam Pharmaceuticals were worth $4,390,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会提交的 13F 文件，沃州银行在 2023 年第四季度将其在阿尼拉姆制药公司（NASDAQ:ALNY - 免费报告）股票中的持股比例提高了 127.1%。该公司在此期间额外购买了 6,177 股后，持有 11,037 股生物制药公司的股票。根据其最近的 SEC 文件，沃州银行在阿尼拉姆制药的持股价值为 4,390,000 美元。</p>
</div><ul>
<li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>阿尼拉姆股票飙升 65%：了解背后的原因</li>
</ul>
</div><p>A number of other institutional investors also recently modified their holdings of ALNY. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $32,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 92.97% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也调整了他们在 ALNY 的持股。Root Financial Partners LLC 在第三季度收购了价值 25,000 美元的阿尼拉姆制药新股份。凯通国际资产管理有限公司在第三季度收购了价值 29,000 美元的阿尼拉姆制药新股份。Ameriflex Group Inc.在第三季度收购了价值 32,000 美元的阿尼拉姆制药新股份。Aster Capital Management DIFC Ltd 在第三季度收购了价值 36,000 美元的阿尼拉姆制药新股份。最后，Newbridge Financial Services Group Inc.在第三季度收购了价值 39,000 美元的阿尼拉姆制药新股份。机构投资者和对冲基金持有该公司 92.97% 的股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 21,255 shares of company stock worth $6,930,337. Insiders own 0.86% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士梅丽莎·麦克劳林于 4 月 6 日星期一出售了 2,286 股公司的股票。该股票以平均价格 330.42 美元出售，总交易额为 755,340.12 美元。交易完成后，内部人士直接持有公司 9,443 股，价值 3,120,156.06 美元。此次交易使其持股减少了 19.49%。该销售在向证券交易委员会的文件中披露，相关信息可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此次出售是为了覆盖与股权奖励归属相关的税收扣缴义务。此外，执行副总裁凯文·约瑟夫·菲茨杰拉德于 3 月 3 日星期二出售了 1,652 股公司的股票。该股票以平均价格 319.73 美元出售，总价值为 528,193.96 美元。交易完成后，执行副总裁持有公司 21,860 股，价值约 6,989,297.80 美元。此次交易使其持股减少了 7.03%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了价值 6,930,337 美元的 21,255 股公司股票。内部人士持有公司 0.86% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 biotech powerhouses poised to thrive amid sector rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
</div><p>Several equities research analysts have recently issued reports on ALNY shares. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 17th. Bank of America reiterated a &#34;buy&#34; rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Jefferies Financial Group reaffirmed a &#34;hold&#34; rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a research note on Monday, May 4th. Finally, Freedom Capital raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $463.13.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 ALNY 股票发布了报告。Canaccord Genuity Group 将阿尼拉姆制药的目标价从 415.00 美元上调至 429.00 美元，并在 2 月 17 日的报告中给予该公司 “买入” 评级。美国银行在 2 月 12 日的报告中重申了对阿尼拉姆制药股票的 “买入” 评级。杰富瑞金融集团在 3 月 16 日的研究报告中重申了 “持有” 评级，并将阿尼拉姆制药的目标价设定为 330.00 美元（低于 522.00 美元）。Weiss Ratings 在 5 月 4 日的研究报告中将阿尼拉姆制药的评级从 “卖出（d+）” 上调至 “持有（c-）”。最后，Freedom Capital 在 2 月 17 日的研究报告中将阿尼拉姆制药的评级从 “持有” 上调至 “强烈买入”。两位研究分析师给予该股票 “强烈买入” 评级，十八位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat.com 的数据，阿尼拉姆制药目前的平均评级为 “适度买入”，共识目标价为 463.13 美元。</p>
</div><p><strong>View Our Latest Analysis on Alnylam Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对阿尼拉姆制药的最新分析</strong></p>
</div><h2>Alnylam Pharmaceuticals Stock Up 1.4%</h2>
<div class="lb-trans"><h2>阿尼拉姆制药股票上涨 1.4%</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>阿根克斯 28% 的激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Shares of Alnylam Pharmaceuticals stock opened at $298.48 on Thursday. The stock has a market capitalization of $39.85 billion, a P/E ratio of 81.55 and a beta of 0.31. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The stock has a 50 day moving average price of $312.06 and a two-hundred day moving average price of $361.02. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.19 and a 12-month high of $495.55.</p>
<div class="lb-trans"><p>阿尼拉姆制药的股票在周四以 298.48 美元开盘。该股票的市值为 398.5 亿美元，市盈率为 81.55，贝塔系数为 0.31。该公司的速动比率为 3.06，流动比率为 3.13，债务与股本比率为 0.94。该股票的 50 日移动平均价格为 312.06 美元，200 日移动平均价格为 361.02 美元。阿尼拉姆制药公司 12 个月低点为 284.19 美元，12 个月高点为 495.55 美元。</p>
</div><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business's revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.44) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿尼拉姆制药（NASDAQ:ALNY - 获取免费报告）最近于 4 月 30 日发布了其财报。这家生物制药公司报告了每股收益 1.99 美元，超出分析师一致预期的 0.87 美元，超出幅度为 1.12 美元。该公司在本季度的收入为 11.7 亿美元，而分析师预期为 11.2 亿美元。阿尼拉姆制药的净利润率为 11.72%，股本回报率为 85.76%。该公司的收入同比增长 96.4%。在去年同期，该公司每股收益为（0.44）美元。股票分析师预计阿尼拉姆制药将在当前年度发布每股收益 7.36 美元。</p>
</div><h2>About Alnylam Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于阿尼拉姆制药</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.</p>
<div class="lb-trans"><p>阿尼拉姆制药公司（NASDAQ: ALNY）是一家生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。公司成立的目的是将 RNAi 的科学发现转化为新药，阿尼拉姆利用小干扰 RNA（siRNA）技术来沉默致病基因。该公司开发的疗法旨在通过针对一系列罕见和更常见疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
</div><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p>
<div class="lb-trans"><p>阿里拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc-结合化学以实现针对肝脏的靶向递送，并通过皮下给药。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Alnylam Pharmaceuticals</li>
<li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li>
<li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li>
<li>USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms</li>
<li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比阿里拉姆制药更好的股票</li>
<li>从 Zepbound 到 Foundayo：礼来最新业绩支持口服 GLP-1 前景</li>
<li>人工智能整合开始：黑石与谷歌打造人工智能帝国</li>
<li>美国稀土公司在 2026 年第一季度发布强劲业绩，巨额 Serra Vera 交易即将到来</li>
<li>三只在 SpaceX IPO 前获得动力的太空基础设施股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在阿里拉姆制药吗？</h2>
</div><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿里拉姆制药并不在名单上。</p>
</div><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Banque Cantonale Vaudoise Has $4.39 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Market Beat

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

Direxion Daily Biotech Top 5 Bull 2X ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

标普全球医疗股指数 ETF - iShares

美国银行

Jefferies Financial

Argenx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

沃州州立银行持有阿里拉姆制药公司价值 439 万美元的股份，股票代码为$ALNY